Skip to main content
Log in

Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Schmutz M, Brugger F, Gentsch C, McLean MJ, Olpe HR (1994) Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia 35(Suppl 5):S47–S50

    Article  PubMed  Google Scholar 

  2. Theisohn M, Heimann G (1982) Disposition of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers. Eur J Clin Pharmacol 22(6):545–551

    Article  CAS  PubMed  Google Scholar 

  3. Schutz H, Feldmann KF, Faigle JW, Kriemler HP, Winkler T (1986) The metabolism of 14C-oxcarbazepine in man. Xenobiotica 16(8):769–778

    Article  CAS  PubMed  Google Scholar 

  4. Patsalos PN, Zakrzewska JM, Elyas AA (1990) Dose dependent enzyme induction by oxcarbazepine? Eur J Clin Pharmacol 39(2):187–188

    Article  CAS  PubMed  Google Scholar 

  5. Arnoldussen WHJ, Rentmeester T (1993) Interaction between oxcarbazepine and phenytoin. Epilepsia 34(Suppl. 6):37

    Google Scholar 

  6. Barcs G, Walker EB, Elger CE, Scaramelli A, Stefan H, Sturm Y, Moore A, Flesch G, Kramer L, D’Souza J (2000) Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 41(12):1597–1607

    Article  CAS  PubMed  Google Scholar 

  7. McKee PJ, Blacklaw J, Forrest G, Gillham RA, Walker SM, Connelly D, Brodie MJ (1994) A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 37(1):27–32

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Tartara A, Galimberti CA, Manni R, Morini R, Limido G, Gatti G, Bartoli A, Strada G, Perucca E (1993) The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br J Clin Pharmacol 36(4):366–368

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT (2003) Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 42(9):819–850. doi:10.2165/00003088-200342090-00003

    Article  CAS  PubMed  Google Scholar 

  10. Armijo JA, Vega-Gil N, Shushtarian M, Adin J, Herranz JL (2005) 10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs. Ther Drug Monit 27(2):199–204

    Article  CAS  PubMed  Google Scholar 

  11. de Jesus AN, Wichert-Ana L, Coelho EB, Della Pasqua O, Alexandre Junior V, Takayanagui OM, Tozatto E, Marques MP, Lanchote VL (2015) Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. Eur J Clin Pharmacol. doi:10.1007/s00228-015-1970-4

    Google Scholar 

  12. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Muller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44(6):195–235

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stefan Weiler.

Ethics declarations

Disclosure

We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Conflict of interest

The authors declare that they have no competing interests. All authors had access to the data and a role in writing the manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sigaroudi, A., Kullak-Ublick, G.A. & Weiler, S. Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine. Eur J Clin Pharmacol 72, 377–378 (2016). https://doi.org/10.1007/s00228-015-1991-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-015-1991-z

Keywords

Navigation